INDIANAPOLIS (WISH) — The U.S. Environmental Protection Agency will hold two open houses next week over plans to cleanup groundwater near the Reilly Tar Superfund site. The site is located on ...

The GTA 5 map comprises the fictional locations of Los Santos, Blaine County, and the neighbouring wilderness of Mount Chiliad. While the map isn't as big as real-life Los Angeles, it's still larger ...

Four-star transfer prospect Desmond Claude — no relation to 2024-25 Tar Heel reserve forward Ty Claude — is considering the UNC basketball program as his next landing spot, On3's Joe Tipton ...

The TAR-200 system offering sustained intravesical gemcitabine release shows favorable response and tolerability in both the CIS and papillary-only subgroups with BCG-unresponsive high-risk NMIBC.

Early findings from Johnson & Johnson’s Phase IIb SunRISe-1 trial show the promise of TAR-200 in patients with Bacillus Calmette-Guérin–unresponsive, high-risk non–muscle-invasive bladder cancer, ...

Now, the college football coach’s girlfriend is reportedly becoming a concern for the North Carolina Tar Heels and those close to him. According to TMZ, people working at the University of North ...

CBS News' data team created an interactive map that shows where cicadas are expected to be this year. The map uses information from the University of Connecticut's Cicada Project, which plots the ...

TAR-200 demonstrated high DFS and bladder preservation rates in BCG-unresponsive, high-risk non-muscle-invasive bladder cancer with papillary-only disease. The phase 2b SunRISe-1 study showed over 80% ...

You can save this article by registering for free here. Or sign-in if you have an account. Federal election results are flowing in. Find out the composition of Canada’s next Parliament. Enjoy ...

US healthcare giant Johnson & Johnson (NYSE: JNJ) has shared new findings for TAR-200, an intravesical gemcitabine releasing system, for patients with BCG-unresponsive high-risk non-muscle invasive ...

"These results demonstrate that TAR-200 can be a meaningful alternative to surgery that is both effective and well-tolerated while preserving the bladder." Among the 52 patients enrolled, the safety ...

Felix Guerrero-Ramos, MD, PhD, discusses findings from cohort 4 of the phase 2 SunRISe-1 trial of TAR-200 in patients with high-risk, BCG-unresponsive NMIBC with papillary-only disease. Felix Guerrero ...